CAPLIN POINT LABORATORIES
|
CAPLIN POINT LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 70.57 | 60.18 | 49.57 | 39.56 | 32.03 |
| CEPS(Rs) | 79.88 | 67.79 | 55.60 | 46.88 | 38.12 |
| DPS(Rs) | 6.00 | 5.00 | 4.50 | 4.00 | 3.00 |
| Book NAV/Share(Rs) | 362.67 | 293.21 | 235.91 | 183.89 | 144.94 |
| Tax Rate(%) | 20.05 | 18.25 | 16.48 | 20.05 | 19.83 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 33.39 | 32.55 | 30.03 | 31.08 | 30.55 |
| EBIT Margin(%) | 34.96 | 33.36 | 30.83 | 30.45 | 29.70 |
| Pre Tax Margin(%) | 34.93 | 33.32 | 30.77 | 30.39 | 29.55 |
| PAT Margin (%) | 27.93 | 27.24 | 25.70 | 24.30 | 23.69 |
| Cash Profit Margin (%) | 31.33 | 30.39 | 28.77 | 27.99 | 27.17 |
| Performance Ratios | |||||
| ROA(%) | 18.37 | 18.98 | 19.30 | 19.94 | 20.20 |
| ROE(%) | 21.72 | 22.97 | 23.68 | 24.77 | 25.65 |
| ROCE(%) | 26.22 | 26.92 | 26.85 | 28.77 | 28.82 |
| Asset Turnover(x) | 0.66 | 0.70 | 0.75 | 0.82 | 0.85 |
| Sales/Fixed Asset(x) | 2.48 | 2.86 | 3.17 | 2.92 | 2.73 |
| Working Capital/Sales(x) | 1.06 | 1.08 | 1.14 | 1.16 | 1.22 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.40 | 0.35 | 0.32 | 0.34 | 0.37 |
| Receivable days | 110.70 | 100.92 | 88.48 | 85.74 | 87.41 |
| Inventory Days | 65.86 | 70.16 | 64.15 | 58.42 | 71.75 |
| Payable days | 105.88 | 96.31 | 84.89 | 80.02 | 59.05 |
| Valuation Parameters | |||||
| PER(x) | 28.38 | 21.89 | 12.04 | 17.19 | 12.62 |
| PCE(x) | 25.07 | 19.43 | 10.73 | 14.50 | 10.60 |
| Price/Book(x) | 5.52 | 4.49 | 2.53 | 3.70 | 2.79 |
| Yield(%) | 0.30 | 0.38 | 0.75 | 0.59 | 0.74 |
| EV/Net Sales(x) | 7.59 | 5.62 | 2.80 | 3.75 | 2.55 |
| EV/Core EBITDA(x) | 19.78 | 15.41 | 8.28 | 11.00 | 7.70 |
| EV/EBIT(x) | 21.71 | 16.86 | 9.10 | 12.33 | 8.60 |
| EV/CE(x) | 5.16 | 4.11 | 2.18 | 2.75 | 1.99 |
| M Cap / Sales | 7.86 | 5.91 | 3.09 | 4.06 | 2.88 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 14.37 | 15.50 | 15.54 | 19.61 | 22.95 |
| Core EBITDA Growth(%) | 20.21 | 24.41 | 14.68 | 23.07 | 16.85 |
| EBIT Growth(%) | 19.85 | 25.01 | 16.97 | 22.62 | 16.84 |
| PAT Growth(%) | 17.27 | 22.40 | 22.22 | 22.68 | 16.90 |
| EPS Growth(%) | 17.25 | 21.40 | 25.32 | 23.52 | 12.67 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | 0.01 |
| Current Ratio(x) | 6.97 | 5.72 | 5.79 | 6.25 | 7.10 |
| Quick Ratio(x) | 5.88 | 4.62 | 4.72 | 5.15 | 5.85 |
| Interest Cover(x) | 1,110.48 | 724.63 | 579.65 | 552.17 | 198.25 |
| Total Debt/Mcap(x) | - | - | - | - | 0.01 |
Compare Financial Ratios of peers of CAPLIN POINT LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CAPLIN POINT LABORATORIES | ₹14,060.4 Cr | -1.7% | -2.1% | -28.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹414,929.0 Cr | 0.7% | -4.2% | -8.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹169,644.0 Cr | 0% | -1% | 4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹131,481.0 Cr | 2.4% | 4.5% | 14.5% | Stock Analytics | |
| CIPLA | ₹122,050.0 Cr | 1.1% | 0.2% | -1.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,784.0 Cr | -1% | -2% | -9.7% | Stock Analytics | |
CAPLIN POINT LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CAPLIN POINT LABORATORIES | -1.7% |
-2.1% |
-28.1% |
| SENSEX | 0.9% |
0.7% |
9.6% |
You may also like the below Video Courses
